Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11780840 Tricyclic urea compounds as JAK2 V617F inhibitors

Patent 11780840 was granted and assigned to Incyte on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Current Assignee

Incyte

Date Filed

July 1, 2021

Date of Patent

October 10, 2023

Patent Applicant

Incyte

Patent Application Number

17365789

Patent Citations

‌

US Patent 8637235 Identification of a JAK2 mutation in polycythemia vera

‌

US Patent 7429456 Identification of a JAK2 mutation in Polycythemia Vera

‌

US Patent 7781199 Identification of a JAK2 mutation involved in Vaquez Polyglobulia

‌

US Patent 7879844 Heterocyclic janus kinase 3 inhibitors

‌

US Patent 8163767 Heterocyclic Janus Kinase 3 inhibitors

‌

US Patent 8524867 Optimized antibodies that target CD19

‌

US Patent 10287303 Compositions and methods for inhibiting arginase activity

‌

US Patent 10377759 Brk inhibitory compound

‌

US Patent 8785639 Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

‌

US Patent 8852931 Identification of a JAK2 mutation involved in vaquez polyglobulia

•••

Patent Citations Received

‌

US Patent 12084430 Tricyclic urea compounds as JAK2 V617F inhibitors

‌

US Patent 11958861 Spirocyclic lactams as JAK2 V617F inhibitors

Patent Inventor Names

David M. Burns

Onur Atasoylu

Song Mei

Joseph Barbosa

Haisheng Wang

Eddy W. Yue

Leah C. Konkol

Jun Pan

Yu Bai

Hao Feng

•••

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11780840

Patent Primary Examiner

CPC Code

Find more entities like US Patent 11780840 Tricyclic urea compounds as JAK2 V617F inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.